Trump says envoy Witkoff had productive meeting with Putin
Investing.com - Cantor Fitzgerald raised its price target on Zevra Therapeutics, Inc. (NASDAQ:ZVRA) to $29.00 from $25.00 on Thursday, while maintaining an Overweight rating on the stock. The company’s shares, currently trading at $11.56, have surged nearly 19% in the past week and doubled over the last year, according to InvestingPro data.
The increase follows significant developments in Zevra’s arimoclomol program for Niemann Pick Disease Type C (NPC), including the publication of a mechanistic study and advancement toward potential European Union approval. With analysts forecasting sales growth and profitability this year, InvestingPro subscribers can access 16 additional investment tips and comprehensive analysis in the Pro Research Report.
Cantor Fitzgerald noted that the mechanistic study provides valuable insights into the cellular pathways through which arimoclomol works, which should improve physician comfort and potentially increase patient uptake.
The investment firm highlighted the unique market opportunity in Europe for Zevra’s NPC treatment, describing it as an established market due to the existing usage of miglustat for the condition.
Despite expectations of lower pricing in Europe compared to the United States, Cantor Fitzgerald believes the total addressable market in Europe could ultimately be similar in size to the U.S. market.
In other recent news, Zevra Therapeutics reported a net loss of $3.1 million for the first quarter of 2025, equating to a loss of $0.06 per share. The company achieved revenue of $20.4 million, primarily driven by its MyPlifa product, which exceeded the forecasted revenue of $16.02 million. H.C. Wainwright initiated coverage on Zevra Therapeutics with a Buy rating, citing the company’s successful transition to a commercial-stage rare disease entity and the promising U.S. launch of Miplyffa for Niemann-Pick disease type C. The research firm suggested that Zevra’s stock remains undervalued, particularly with the European market opportunity for Miplyffa representing a significant growth driver. Additionally, Zevra confirmed the re-election of Wendy L. Dixon, Ph.D., and Tamara A. Favorito to its Board of Directors, highlighting stockholder support for the company’s strategic direction. During the 2025 Annual Meeting of Stockholders, Ernst & Young LLP was approved as the independent auditor for the fiscal year ending December 31, 2025. Zevra is advancing its European regulatory submissions for MyPlifa, aiming to expand its market presence beyond the United States.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.